Fengjuan Wang

Fengjuan Wang has a wealth of experience in the field of business development, innovation, and research. Fengjuan began their career in 2012 as a Visiting Researcher at Centro de Investigaciones Biológicas - CSIC, supported by the EpitopeMap grant from the European Science Foundation. Here, they were trained in lysosomal dysfunctions and autophagy in disease and development. In 2013, they began a Postdoctoral Researcher role at Centre national de la recherche scientifique, where they focused on peptide-cell interaction for lupus therapy, demonstrating that a lupus therapeutic peptide targets lysosomes and autophagy. In 2018, they moved to CardioRenal as an Innovation Manager. Finally, in 2022, they became a Business Development Manager at Domain Therapeutics.

Fengjuan Wang obtained a Bachelor's Degree in Chemcial Biology from Hubei University between 2004 and 2008. In 2007, they also obtained an English Interpreting Certificate Level 2 from Xiamen University. Fengjuan then went on to pursue a Doctor of Philosophy (Ph.D.) in Nanomedicine and Cell Biology from University College Dublin, which they completed in 2012.